Filing Flows › QuidelOrtho (QDEL) › Q3 2026 › vs Q3 2025
QuidelOrtho (QDEL) Q3 2026 vs Q3 2025 (year over year)
QuidelOrtho's revenue fell $81.0M (-12%) from $700M in Q3 2025 to $619M in Q3 2026.
QuidelOrtho, Q3 2026: revenue $619M (-12% year over year), operating margin -1.2%, net loss $53.8M, operating cash flow $19.6M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $619M | $700M | −$81.0M | -12% |
| Income tax benefit | $9.1M | $23.9M | −$14.8M | -62% |
| Net loss | $53.8M | $733M | −$679M | -93% |
| Costs & expenses | $682M | $1.5B | −$775M | -53% |
| Operating costs | $626M | $1.4B | −$778M | -55% |
| Interest & other, net | $55.4M | $52.1M | $3.3M | +6% |
| Cost of revenue | $329M | $364M | −$35.0M | -10% |
| Research & development | $42.5M | $41.5M | $1.0M | +2% |
| SG&A | $183M | $187M | −$4.2M | -2% |
| Other operating costs | $71.9M | $812M | −$740M | -91% |
| Operating cash sources | $132M | $123M | $8.8M | +7% |
| Depreciation & amortization | $120M | $112M | $7.5M | +7% |
| Share-based compensation | $12.0M | $10.7M | $1.3M | +12% |
| Net loss absorbed | $53.8M | $733M | −$679M | -93% |
| Working capital & other | $58.2M | −$565M | $623M | — |
| Operating cash flow | $19.6M | −$45.5M | $65.1M | — |
Questions
How much did QuidelOrtho's revenue grow year over year in Q3 2026?
QuidelOrtho's revenue fell $81.0M (-12%) from $700M in Q3 2025 to $619M in Q3 2026.